From GlobeNewswire: 2025-06-30 03:00:00

Rakovina Therapeutics Inc. shared its H1 2025 accomplishments and strategic objectives for H2 2025, focusing on AI-powered drug discovery in the global landscape. AstraZeneca signed a $5.3 billion drug discovery agreement with CSPC Pharmaceutical Group, highlighting the momentum of AI in medicine. Rakovina utilizes exclusive AI platforms like Deep Docking™ & Enki™, accelerating drug discovery with machine learning. The company aims to collaborate on lead candidate development, advance preclinical therapies, and secure funding for expanded activities in oncology. Rakovina’s Executive Chairman emphasized the role of AI in drug development, positioning the company as a leader in cancer therapeutics.



Read more at GlobeNewswire: Rakovina Therapeutics Highlights Strong H1 Progress and